Drug profile · INN
paliperidone palmitate
PALIPERIDONE PALMITATE
paliperidone palmitate (PALIPERIDONE PALMITATE) is a serotonin 2a (5-ht2a) receptor antagonist. Route of administration: intramuscular. Current US regulatory status: approved.
Drug details — paliperidone palmitate
- US status
- approved
- Class
- —
- Route
- INTRAMUSCULAR
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
paliperidone palmitate (PALIPERIDONE PALMITATE) is a serotonin 2a (5-ht2a) receptor antagonist. Route of administration: intramuscular. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 2a (5-HT2a) receptor antagonist
Primary target: D(2) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is paliperidone palmitate?
paliperidone palmitate (PALIPERIDONE PALMITATE) is a serotonin 2a (5-ht2a) receptor antagonist. Route of administration: intramuscular. Current US regulatory status: approved.
What is the brand name for paliperidone palmitate?
PALIPERIDONE PALMITATE is a marketed brand name for paliperidone palmitate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of paliperidone palmitate?
paliperidone palmitate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.